Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A labeling team facing a boxed-warning debate cannot treat a payer demanding RWE the protocol cannot generate as incidental context on scientific-advice briefing book. Pharmacovigilance medical reviewer must close to drop a secondary from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. A payer demanding RWE the protocol cannot generate is noise around an already-controlled Pharmacovigilance process in a labeling team facing a boxed-warning debate, given scientific-advice briefing book. 2. A payer demanding RWE the protocol cannot generate is the event in scientific-advice briefing book that forces Proceed under protocol for pharmacovigilance medical reviewer under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after a payer demanding RWE the protocol cannot generate, not a Pharmacovigilance program failure. 4. Scientific-advice briefing book cannot decide to drop a secondary yet after a payer demanding RWE the protocol cannot generate; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim pharmacovigilance medical reviewer would keep. 2. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a payer demanding RWE the protocol cannot generate. 4. For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after a payer demanding RWE the protocol cannot generate). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate - What changes to drop a secondary if a payer demanding RWE the protocol cannot generate is later withdrawn